AJMC January 4, 2025
Kyle Munz

Tim Mok, PharmD, BCPS, BCOP, malignant hematology pharmacy research analyst at Kaiser Permanente, discussed his perspective on the balance between clinical outcomes and cost considerations.

Tim Mok, PharmD, BCPS, BCOP, malignant hematology pharmacy research analyst at Kaiser Permanente, was the featured moderator of “Pharmacy Decision-Making in Value-Based Care,” a panel conducted at a recent Institute for Value-Based Medicine event in Seattle, Washington. As the panelists explored the intricacies of multidisciplinary collaboration and pharmacy decision making, Mok joined for an interview to discuss his perspective on how to best strike a balance between clinical outcomes and cost considerations. Here, he highlights the value of real-world evidence, prominent challenges in the field, and more.

This transcript has been lightly edited.

Transcript

In...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Conferences / Podcast, Pharma, Pharma / Biotech, Trends
The Future Of Pharmacies In 3 Scenarios - 2
Will AI revolutionize drug development? Researchers explain why it depends on how it's used
CVS Health launches CostVantage model
A Startup’s €90M Financing for Oral Peptide Drugs Includes Backing from Eli Lilly
An evolution in leadership and vision for this pharma company

Share This Article